Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC

被引：27

作者：

Gissen, P

Preece, MA

Willshaw, HA

McKiernan, PJ

机构：

[1] Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England

[2] Birmingham Childrens Hosp, Dept Clin Chem, Birmingham B4 6NH, W Midlands, England

[3] Birmingham Childrens Hosp, Dept Ophthalmol, Birmingham B4 6NH, W Midlands, England

来源：

JOURNAL OF INHERITED METABOLIC DISEASE | 2003年 / 26卷 / 01期

关键词：

D O I：

10.1023/A:1024011110116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.

引用

页码：13 / 16

页数：4

共 50 条

[31] FOLLOW-UP ADHERENCE IN PATIENTS WITH NONPROLIFERATIVE DIABETIC RETINOPATHY PRESENTING TO AN OPHTHALMIC EMERGENCY DEPARTMENT
Watane, Arjun
Kalavar, Meghana
Vanner, Elizabeth A.
Cavuoto, Kara
Sridhar, Jayanth
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2021, 41 (06): : 1293 - 1301
[32] Islet transplantation in patients with type I diabetes. Results of 10 years follow-up
Maffi, P
Bertuzzi, F
Aldrighetti, L
Angeli, E
Nano, R
Pozza, G
Di Carlo, V
Secchi, A
TRANSPLANTATION, 2000, 69 (08) : S268 - S268
[33] Fumarylacetoacetase mutations in tyrosinaemia type I
Rootwelt, H
Hoie, K
Berger, R
Kvittingen, EA
HUMAN MUTATION, 1996, 7 (03) : 239 - 243
[34] Optimal follow-up of stage I colorectal cancer patients
Higuchi, Tetsuro
Enomoto, Masayuki
Sugihara, Kenichi
GASTROENTEROLOGY, 2006, 130 (04) : A867 - A867
[35] Liver transplantation in tyrosinaemia type I
Baumann, U
Rodeck, B
MONATSSCHRIFT KINDERHEILKUNDE, 2004, 152 (10) : 1102 - 1106
[36] Tyrosinemia type 1, follow up of 8 patients treated with phenylalanine (Phe) and tyrosine (Tyr) restricted diet and NTBC
Raimann, E.
Cornejo, V
Castro, G.
Valiente, A.
Cabello, J. F.
JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 : 108 - 108
[37] A review of 145234 ophthalmic patient episodes lost to follow-up
Davis, A.
Baldwin, A.
Hingorani, M.
Dwyer, A.
Flanagan, D.
EYE, 2017, 31 (03) : 422 - 429
[38] Long-term neuropsychiatric follow-up in hyperprolinemia type I
Di Rosa, Gabriella
Nicotera, Antonio G.
Lenzo, Patrizia
Spano, Maria
Tortorella, Gaetano
PSYCHIATRIC GENETICS, 2014, 24 (04) : 172 - 175
[39] Follow-up of type 2 diabetes patients (excluding complications)
Charbonnel, B
Aptel, I
Amouyel, P
Attali, JR
Aulanier, S
Balarac, N
Bukowski, JV
Cathelineau, B
de Broucker, T
Denis, C
Mausset, J
Ormières, JJ
Passa, P
Paulhan, A
Pousset, F
Pouteil-Noble, C
Laversin, S
Anouchian, P
Aquino, JP
Aubert, JP
Baufine-Ducrocq, H
Bernard, MH
Bonnet, A
Chabassol, E
Cirioni, A
Colas, C
Cordonnier, D
Coscas, G
Cuvelier, D
Dany, F
Derrien, G
Desrousseaux, B
Dueymes, JM
Dupasquier, JP
Dussart, L
Gemez-Lestradet, C
Gerson, M
Grimaldi, A
Gros, M
Guerot, C
Guyot-Argenton, C
Halimi, S
Kourilsky, O
Lanéelle, D
Laudet, J
Lelong, S
Malinsky, M
Meffre, C
Moulin, P
Olaya, E
PRESSE MEDICALE, 1999, 28 (19): : 1023 - 1027
[40] Telemedicine Influence on the Follow-Up of Type 2 Diabetes Patients
Rodriguez-Idigoras, Maria I.
Sepulveda-Munoz, Jesus
Sanchez-Garrido-Escudero, Ramon
Martinez-Gonzalez, Jose L.
Escolar-Castello, Jose L.
Paniagua-Gomez, Isabel M.
Bernal-Lopez, Rosa
Fuentes-Simon, Maria V.
Garofano-Serrano, Daniel
DIABETES TECHNOLOGY & THERAPEUTICS, 2009, 11 (07) : 431 - 437

← 1 2 3 4 5 →